Outdated printed leaflets often leave patients and healthcare professionals without the most current medicinal information, creating risks for treatment safety and compliance. Electronic Product Information (ePI) offers a fast, reliable way to ensure e-labelling access anytime and anywhere, across multiple digital channels. By integrating real-time updates, multilingual support, and user-friendly formats, ePI bridges the gap between regulatory requirements and the need for accurate, accessible product data. 

How does ePI improve e-labelling access for patients and healthcare professionals? 

At Billev Pharma East, we facilitate the seamless and compliant deployment of electronic Product Information (ePI). By aligning with EMA and EU regulations, we help ensure that e-labelling is implemented efficiently—so that healthcare professionals and patients gain immediate, accurate, and regulatorily sound access to up-to-date medicine information. 

ePI allows patients and healthcare professionals to always have the latest approved product information, reducing risks linked to outdated printed leaflets. Patients can access this data anytime through digital devices, while healthcare professionals benefit from faster updates and reduced administrative delays. 

Digital health tools like ePI also support medication adherence and improve patient safety by making critical information more accessible. Centralised updates mean that once information is revised, it becomes instantly available across all channels, without printing or distribution lag. 

By adopting structured formats, QR or 2D matrix code access, and multilingual capabilities, ePI bridges the gap between regulatory compliance and user-friendly information delivery. This ensures safer healthcare outcomes and aligns with the EU’s vision for a paperless, sustainable approach to medicinal product communication. 

What are the most effective digital channels for delivering ePI content? 

Selecting the right digital channels is key to optimising e-labelling access. As highlighted in our electronic leaflet resources, the goal is to reach users through platforms they already use and trust. 

Web-based portals and mobile applications are among the most effective ways to distribute ePI, especially when paired with QR or 2D matrix codes on packaging. QR or 2D matrix technology provides a link between the physical product and the latest approved digital leaflet. 

Integration into healthcare provider systems, such as electronic health records (EHR), ensures that clinicians always consult the most up-to-date product data. Multi-channel delivery—combining mobile, web, and integrated clinical systems—significantly increases patient engagement and understanding. 

Social media and professional healthcare platforms can complement these core channels by raising awareness of ePI availability. A multi-channel strategy not only widens reach but also ensures redundancy: if one channel fails, others remain available, safeguarding uninterrupted e-labelling access. 

How can regulatory compliance be ensured while enhancing e-labelling access? 

Experts at Billev Pharma East support your company in establishing robust, regulatory-aligned procedures to effectively manage and govern electronic Product Information (ePI), ensuring seamless integration into regulatory workflows. 

Balancing regulatory compliance with efficient e-labelling access requires meticulous processes. Each jurisdiction—whether under EMA, FDA, or other national agencies across the globe — has its own standards for format, approval, and distribution. Industry would like to see one global standard for implementation of e-labelling, such as FHIR. 

Structured formats such as HL7 FHIR or XML enable easy updating and regulatory review. Organisations must maintain detailed version control and audit trails to demonstrate compliance during inspections. 

Regular dialogue with regulators ensures alignment with evolving digital standards. For global distribution, adopting international identification and data exchange guidelines ensures consistent terminology and content accuracy. 

Embedding compliance checks into the publishing workflow—using automated validation tools—helps detect errors early. This way, companies protect both patient safety and their market authorisation, while ensuring e-labelling access remains fast and reliable. 

Key regulatory requirements impacting e-labelling access 

Ensuring e-labelling access in a compliant way means understanding and aligning with the specific regulatory requirements of each target market. While global initiatives aim for harmonisation, there are still significant differences between regions in terms of accepted formats, update cycles, and mandatory content. 

For example, the European Medicines Agency (EMA) supports structured XML-based ePI formats to ensure interoperability and fast updates, while the U.S. Food and Drug Administration (FDA) mandates Structured Product Labeling (SPL) in XML but has different update frequency expectations. The World Health Organization (WHO) also recommends multilingual and accessible formats, particularly for low-resource settings. 

The table below summarises some of the key regional differences that pharmaceutical companies must navigate when implementing ePI solutions: 

By mapping these regulatory landscapes early, companies can design workflows that enable fast, compliant updates without disrupting e-labelling access. This approach not only meets legal obligations but also builds trust with healthcare professionals and patients who rely on accurate, timely information. 

Which user experience factors matter most for successful ePI implementation? 

The success of e-labelling access depends on user experience (UX) design. Health information tools must be inclusive and intuitive to achieve adoption. 

Critical UX elements include clear navigation, responsive design, and multilingual support. Accessibility features such as adjustable font size, high-contrast mode, and text-to-speech capabilities are essential for elderly users and those with visual impairments. 

Patients report higher satisfaction when ePI platforms provide search filters, infographics, and mobile-optimised interfaces. Regular usability testing with both patients and healthcare providers can identify friction points and guide continuous improvements. 

By prioritising accessibility, simplicity, and clarity, ePI platforms can maximise engagement and ensure e-labelling access delivers real-world benefits.

How does multilingual support impact global e-labelling access? 

Global medicine distribution makes multilingual content a necessity for effective e-labelling access. Product information must be available in the official languages of the countries where the product is marketed. 

True multilingual support goes beyond translation—it involves localisation, adapting terminology, regulatory wording, and cultural nuances. This reduces the risk of misunderstandings that could impact patient safety. 

Technology solutions like translation memory systems and automated update synchronisation ensure that all language versions are aligned and updated simultaneously, reducing regulatory risk. This approach fosters trust, compliance, and patient empowerment across diverse markets. 

Multilingual implementation strategies for better e-labelling access 

Providing multilingual product information is essential for ensuring e-labelling access in global markets. However, true effectiveness goes beyond literal translation — it requires localisation that considers regulatory language requirements, cultural nuances, and technical constraints of the EPI platform. 

Localisation ensures that medical terms are accurate and comply with national standards, while also adapting date formats, measurement units, and even colour schemes for better user comprehension. Some regions also mandate that product information be available in multiple official languages, with strict timelines for simultaneous release. 

By integrating translation memory tools, automated update synchronisation, and rigorous quality checks, companies can ensure consistent and accurate content across all required languages. This proactive approach supports global compliance, enhances trust, and significantly improves e-labelling access for diverse patient populations. 

What role does mobile technology play in increasing ePI reach? 

Mobile technology is one of the most effective drivers of e-labelling access. With the majority of adults owning smartphones, mobile access to ePI is a practical reality. 

Mobile apps can deliver offline access, update alerts, and interactive features like QR or 2D matrix code scanning for instant leaflet retrieval. Mobile-optimised drug information enhances patient engagement and improves clinical decision-making at the point of care. 

For healthcare providers, mobile ePI ensures fast reference during consultations, supporting safer prescribing and dispensing practices. 

How can data analytics help optimise digital EPI delivery strategies?

Data analytics enables continuous improvement in e-labelling access strategies. By tracking user behaviour—such as device type, peak access times, and content viewed—organisations can refine delivery methods.

Analytics can identify which channels drive the most engagement and which leaflet sections users spend the most time on. These insights can guide content layout, prioritisation, and even regulatory update cycles.

Predictive analytics can anticipate demand spikes, such as during flu season, and enable proactive content distribution. Over time, a data-driven approach ensures EPI is not only compliant but also user-centric and effective in reaching its intended audience.

Read also:

• What is structured product labeling and why is it essential for high-quality EPI?
• How does e-labelling help us understand what is electronic product information?

Sources: 1 – Health Policy Partnership